modelNorgestrelAndEthinylestr
Extends from Pharmacolibrary.Drugs.ATC.G.G03AA06.
Information
| name: | NorgestrelAndEthinylestradiol | |
| ATC code: | G03AA06 | route: | oral |
| compartments: | 1 | |
| dosage: | 0.3 | mg |
| volume of distribution: | 1.5 | L |
| clearance: | 0.04 | L/h/kg |
| other parameters in model implementation | ||
Norgestrel and ethinylestradiol is a combination oral contraceptive containing a synthetic progestin (norgestrel) and a synthetic estrogen (ethinylestradiol), primarily used for the prevention of pregnancy. This combination is approved and widely used globally for birth control purposes. It may also be used for menstrual regulation in women.
Pharmacokinetics
Pharmacokinetic parameters reflect healthy adult female volunteers, typically of reproductive age, after administration of a single oral dose corresponding to a standard tablet (norgestrel 0.3 mg and ethinylestradiol 0.03 mg).
References
Mohamed, MF, et al., & Othman, AA (2019). The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. Journal of clinical pharmacology 59(4) 510–516. DOI:10.1002/jcph.1350 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30500075
Kuhnz, W (1990). Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women. American journal of obstetrics and gynecology 163(6 Pt 2) 2120–2127. DOI:10.1016/0002-9378(90)90551-h PUBMED:https://pubmed.ncbi.nlm.nih.gov/2124087
Olsson, B, & Landgren, BM (2001). The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Clinical therapeutics 23(11) 1876–1888. DOI:10.1016/s0149-2918(00)89083-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11768839
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)